Bio-Rad (NYSE: BIO) CFO nets more shares after RSU vesting and tax withholding

Rhea-AI Filing Summary

Bio-Rad Laboratories EVP and Chief Financial Officer Roop Kalyan Lakkaraju reported routine equity compensation activity. On April 24, 2026, 1,078 shares of Class A common stock were acquired upon vesting of restricted stock units and converted from derivative form.

To cover tax obligations, 420 shares were disposed of through a tax-withholding transaction at $287.84 per share, leaving 2,563.895 Class A shares held directly. The filing also notes 2,156 restricted stock units remaining outstanding and references a prior 4,311-unit RSU grant vesting in four annual installments.

Insider Trade Summary

1,078 shares exercised/converted

Mixed 3 txns

Insider Lakkaraju Roop Kalyan

Role EVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	1,078	$0.00	--
Exercise	Bio-Rad A Common Stock	1,078	$0.00	--
Tax Withholding	Bio-Rad A Common Stock	420	$287.84	$121K

Holdings After Transaction: Restricted Stock Units — 2,156 shares (Direct, null); Bio-Rad A Common Stock — 2,983.895 shares (Direct, null)

Footnotes (1)

1. Shares of Class A common stock acquired on the vesting of restricted stock units. Includes 62.2360 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 03/31/2026. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. On April 24, 2024, the reporting person was granted 4,311 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Key Figures

RSUs vested: 1,078 shares Tax-withholding shares: 420 shares Post-transaction holdings: 2,563.895 shares +4 more

7 metrics

RSUs vested 1,078 shares Class A common stock acquired on RSU vesting on April 24, 2026

Tax-withholding shares 420 shares Disposed at $287.84 per share to cover tax liability

Post-transaction holdings 2,563.895 shares Class A common stock held directly after tax-withholding disposition

Remaining RSUs 2,156 units Restricted stock units outstanding after 1,078 units converted

Original RSU grant 4,311 units Granted April 24, 2024, vesting in four equal annual installments

ESPP shares 62.236 shares Acquired under Bio-Rad Employee Stock Purchase Plan on March 31, 2026

Exercise price $0.00 Conversion price per share for RSU-derived Class A common stock

Key Terms

Restricted Stock Units, tax-withholding disposition, derivative security, Bio-Rad Employee Stock Purchase Plan, +1 more

5 terms

Restricted Stock Units financial

"security_title: "Restricted Stock Units" and related RSU vesting details"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax-withholding disposition financial

"transaction_action: "tax-withholding disposition" describing 420-share disposal"

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Bio-Rad Employee Stock Purchase Plan financial

"footnote: "Includes 62.2360 shares acquired under the Bio-Rad Employee Stock Purchase Plan""

contingent right financial

"footnote: "Each restricted stock unit represents a contingent right to receive one share""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lakkaraju Roop Kalyan

(Last) (First) (Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DRIVE

(Street)

HERCULES CALIFORNIA 94547

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Bio-Rad A Common Stock	04/24/2026		M		1,078(1)	A	$0	2,983.895(2)	D
Bio-Rad A Common Stock	04/24/2026		F		420	D	$287.84	2,563.895	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(3)	04/24/2026		M			1,078	(4)	(4)	Bio-Rad A Common Stock	1,078	$0	2,156	D

Explanation of Responses:

1. Shares of Class A common stock acquired on the vesting of restricted stock units.

2. Includes 62.2360 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 03/31/2026.

3. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

4. On April 24, 2024, the reporting person was granted 4,311 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Roop K. Lakkaraju	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did BIO EVP CFO Roop Kalyan Lakkaraju report?

He reported routine equity compensation activity, including vesting of 1,078 restricted stock units into Bio-Rad Class A common shares and a related tax-withholding share disposition. These transactions convert RSUs into shares rather than reflecting an open-market stock purchase or sale.

How many Bio-Rad (BIO) shares did the CFO acquire and dispose in this Form 4?

He acquired 1,078 shares of Bio-Rad Class A common stock through RSU vesting and disposed of 420 shares via a tax-withholding transaction. This left a net increase of 658 shares in his direct holdings, according to the reported post-transaction balances.

What price was used for the BIO CFO’s tax-withholding share disposition?

The tax-withholding disposition for 420 shares of Bio-Rad Class A common stock used a price of $287.84 per share. This transaction pays tax obligations by surrendering shares instead of cash, and is not an open-market sale initiated by the insider.

How many Bio-Rad (BIO) shares does the CFO hold after these transactions?

After the RSU vesting and tax-withholding disposition, the CFO directly holds 2,563.895 shares of Bio-Rad Class A common stock. This figure reflects the net position shown following the tax-withholding transaction recorded in the Form 4 filing.

What restricted stock unit (RSU) position remains for the BIO CFO after this filing?

The filing shows 2,156 restricted stock units remaining after 1,078 units converted into Class A shares. Each RSU represents a contingent right to receive one Bio-Rad Class A share, subject to the original vesting schedule and conditions described in the prior grant.

What prior RSU grant to the BIO CFO is referenced in the footnotes?

Footnotes state that on April 24, 2024, the reporting person was granted 4,311 restricted stock units. These units vest in four equal annual installments beginning on the first anniversary of the grant date, forming the basis for the current 1,078-unit vesting event.

What additional share acquisition under a plan is mentioned for BIO’s CFO?

The footnotes note 62.236 shares acquired under the Bio-Rad Employee Stock Purchase Plan on March 31, 2026. This plan-based acquisition is separate from the RSU vesting and reflects share purchases through an employee stock purchase program at the company.